First Month of GDUFA II Sees Large Spike in Generic CRLs

Drug Industry Daily
A A
In the first month of the GDUFA II program, the FDA sent 325 complete response letters to generics manufacturers — far more than the high of 190 seen in August of the fiscal year before.

To View This Article:

Login

Subscribe To Drug Industry Daily